🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

16 results for “UCB” Clear

  1. Brivaracetam

    UCB Pharma

    Epilepsy

    phase 3 small molecule completed

    1 trial

  2. CHLORURE DE SODIUM 0,9% RENAUDIN, solution injectable, VENLAFAXINE, KETAMINE , 11C-UCB-J

    Pari Pharma GmbH

    Major depressive disorder with current severe major depressive episode

    phase 3 small molecule active

    1 trial

  3. Levetiracetam

    UCB Pharma

    Epilepsy

    phase 3 small molecule completed

    1 trial

  4. Rozanolixizumab, also known as UCB7665, Rystiggo 140 mg/ml solution for injection, -

    Lacuna Pharma Pty Ltd

    Myelin oligodendrocyte glycoprotein antibody-associated disease (MOG-AD)

    phase 3 small molecule active

    1 trial

  5. 11C-UCB-J, 18F-DPA-714, [11C]PiB

    Pari Pharma GmbH

    Alzeihmer disease

    phase 2 small molecule active

    1 trial

  6. CAPECITABINE, CAPECITABINE, NUBEQA 300 mg film-coated tablets

    Ningbo Cancer Hospital

    Triple-negative androgen receptor positive (molecular apocrine-like HER2-negative subtype) locally recurrent (unresectable) or metastatic breast cancer.

    phase 2 small molecule active

    1 trial

  7. umbilical cord blood (hUCB) cells

    S.L

    Cerebral Palsy

    phase 2 mab completed

    1 trial

  8. A study to learn if UCB3101 is safe and how it moves through the body of healthy participants

    Lacuna Pharma Pty Ltd

    Healthy Participants

    phase 1 other active

    1 trial

  9. An open label, balanced, randomized, single dose, two treatment, two period, two sequence, crossover, bioequivalence study comparing Lacosamide tablets USP 200 mg, manufactured by Sun Laboratories Industries Limited, India with Vimpat (Lacosamide) 200 mg film-coated tablets, Marketing Authorisation Holder UCB Pharma S.A., Belgium, in healthy adult, human subjects under fasting condition.

    Lacuna Pharma Pty Ltd

    Epileptic seizures

    phase 1 other active

    1 trial

  10. An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Brivaracetam Tablets Ph. Eur. 100 mg, manufactured by Sun Pharmaceutical Industries Limited, India with Briviact (brivaracetam) 100 mg film-coated tablets, Marketing Authorisation Holder: UCB Pharma S.A., Allée de la Recherche 60, B-1070 Bruxelles, Belgium; Manufactured by UCB Pharma S.A., Chemin du Foriest, B-1420 Braine-l’Alleud, Belgium, in healthy adult, human subjects und

    Lacuna Pharma Pty Ltd

    Epilepsy

    phase 1 other active

    1 trial

  11. HTLP-onco-adult - A phase I/II Study evaluating the safety and the efficacy of Human T Lymphoid Progenitor (HTLP) injection to accelerate immune reconstitution after umbilical cord blood (UCB) transplantation in adult patients with hematologic malignancies

    Pari Pharma GmbH

    hematologic malignancies ; acute myeloid leukemias

    phase 1 other active

    1 trial

  12. Minzasolmin, UCB0599 PRD4385815

    Lacuna Pharma Pty Ltd

    Healthy Participants

    phase 1 small molecule active

    1 trial

  13. Single FT1050 treated UCB unit

    Zafatek

    Non-Hodgkin's Lymphoma (NHL)

    phase 1 mab completed

    1 trial

  14. UCBMC

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Stroke

    phase 1 mab active

    1 trial

  15. hUCB

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Acute Ischemic Stroke

    phase 1 other completed

    1 trial

  16. 11UCB-J PET Scan

    BRIGHT MINDS BIOSCIENCES INC.

    Opiate Dependence

    other completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources